The main problems that cause unresponsiveness to an anti-neoplastic drug are the overexpression of drug resistant and anti-apoptotic proteins in tumor cells. In a rescue protocol we evaluated the ability of toceranib phosphate concurrent with lomustine (CCNU) or L-asparaginase and vincristine to decrease drug resistant and apoptotic proteins in relapsed and refractory canine lymphomas. The peripheral blood samples were collected before and after the rescue treatment from fourteen dogs that were refractory to cyclophosphamide-vincristine-prednisolone (COP) or COP-doxorubicin (CHOP) treatment and had recurrent multicentric lymphoma. The mRNA expression level of ABCB1, ABCG2, Bcl2 and Bax were determined by quantitative real-time PCR. The fold-change in ABCB1, ABCG2, Bcl2 and Bax mRNA levels were analyzed in correlation with the progression-free survival (PFS). After the rescue treatment, the ABCB1 and ABCG2 mRNA expression levels were 1.57-and 1.85-fold lower (p = 0.4 and p = 0.87), respectively, compared to pre-treatment. Bcl2/Bax ratio was numerically but not signifi cantly decreased 1.02-fold (p = 0.74). The overall response rate of this protocol was 50% with a median PFS of 79 days (range 14-207 days). The low medians of relative expression levels of ABCB1, ABCG2 and Bcl2/Bax ratio group did not correlate with the clinical outcomes when compared to the high medians of relative expression levels, and likewise with the clinical stage, immunophenotype, histological grade and sub-stage. Therefore, the administration of a rescue drug with toceranib phosphate might be benefi cial in refractory and relapsed canine lymphoma.
INTRODUCTION
One factor that causes failure in hematological cancer treatments, including canine lymphoma, is the multidrug resistant protein (MRP) mechanism. A member of the ATP-binding cassette (ABC) transporter MRPs, such as P-glycoprotein (Pgp; ABCB1/ MDR1), breast cancer resistance protein (BCRP; ABCG2), multidrug resistance related protein 1 (MRP1; ABCC1), and lung resistance related protein (LRP; LRP1), are expressed as an intra-or extra-cellular membrane component of normal cells. However, they can become over-expressed in tumor cells due to induction by cytotoxic drugs, for example vincristine and doxorubicin [1] , which are used as a standard treatment in canine lymphomas.
The Pgp plays an important role in the MRP mechanism in canine lymphomas. Their expression levels have been detected in previous studies by semi quantitative techniques, such as western blotting [2] , and immunohistochemistry [3, 4] . However, these methods have a low sensitivity and specifi city. Conversely, quantitative real-time PCR (qRT-PCR) shows a greater accuracy in the detection of low ABCB1 transcript levels in normal canine tissues and canine lymphomas [5] . There have been a few studies on the resistant genes that are involved in resistant/relapsed canine multicentric Band T-cell lymphomas, and these have reported the possible involvement of ABCB1 and ABCG2 in terms of their expression levels [6, 7] .
Receptor tyrosine kinases act as cell surface receptors that bind to growth factors and hormones. They are also involved in the control of cell growth and survival. The dysregulation of these receptors is involved in tumorigenesis [8] . In veterinary oncology, the tyrosine kinase inhibitor (TKI) was developed and shown to be an effective treatment drug in canine mast cell tumors and other solid tumors, including canine lymphomas [9] [10] [11] . Moreover, TKI had an inhibitory effect on Pgp function and reverted doxorubicin resistance in canine lymphoma cells [12] .
Failure of cell apoptosis can result in cytotoxic drug resistance. In lymphoid malignancies, the common apoptotic signaling pathway is disturbed through the intrinsic pathway. This pathway is regulated by the related Bcl2 family protein, cell death promoters (BH3-only proteins) and cell death mediators (Bax and Bak). The impaired function of these apoptotic molecules can lead to oncogenesis [13] . For example, mutations in the Bcl2 and tumor suppressor p53 genes that cause loss of Bax activity are frequently involved in human or canine lymphomas [14] [15] [16] [17] [18] . Furthermore, in canine lymphomas, it was reported that T-cell lymphomas had a higher Bcl2/Bax ratio than B-cell lymphomas with poor clinical outcome in the high Bcl2/Bax level group [17] . Thus, Bcl2 and Bax expression might be a meaningful prognostic indicator in dogs with lymphoma.
The common chemotherapy for canine multicentric lymphoma is cyclophosphamidevincristine-prednisolone (COP) or COP-doxorubicin (CHOP) regimes, while the general rescue drugs are lomustine (CCNU) or L-asparaginase. The aim of this study was to determine the favorable effect of the TKI (toceranib phosphate) concurrent with CCNU or L-asparaginase and vincristine as a rescue protocol in refractory and relapsing canine lymphomas that had previously been treated with COP or CHOPbased protocols. The transcript expression level of ABCB1, ABCG2, Bax, and Bcl2 were compared between pre-and post-treatment. The MRP (ABCB1 and ABCG2) transcript levels and Bcl2/Bax transcript ratio were compared with the clinical outcomes.
MATERIALS AND METHODS

Blood sample collection
Peripheral blood samples (1 ml) were collected from 14 dogs between January 2013 and July 2016 at the Oncology Clinic, Small Animal Teaching Hospital, Chulalongkorn University (IACUC Number 13310074). Informed consent has been obtained for client-owned animals included in this study. Each dog was diagnosed as having multicentric lymphoma by histopathology. The immunophenotyping was performed with Pax5 and CD3 as described previously [19] . Five dogs had previously been treated with a modifi ed COP regime, while the other nine dogs were previously treated with a modifi ed CHOP regime. Five of 14 cases (1 COP-treated and 4 CHOP-treated dogs) had a complete remission after treatment and then the disease relapsed after 3-6 months, whereas the others (5 COP-treated and 4 CHOP-treated dogs) showed no response to the current chemotherapy with progressive disease (superfi cial lymph node size was increased in the sum longest diameter more than 20%). A rescue protocol with toceranib phosphate (Palladia, Zoetis, UK) was applied in these cases, as shown in Table 1 , but before giving the rescue treatment, 1 ml of peripheral blood was collected. In addition, seven of these dogs had another 1 ml of blood collected four weeks after applying the rescue treatment. For calibration samples, 3 ml of blood was collected from three healthy dogs with no clinical history of disease. The blood samples from fi ve dogs with naïve canine lymphomas were collected for comparison with animals with relapsed/refractory lymphomas. Peripheral blood samples were collected into EDTA tubes and then centrifuged at 5,000 rpm for 5 min for white blood cell (WBC) separation. The harvested WBC pellet was stored at -80 ºC until subsequent RNA isolation. 
Follow up case
Every dog was evaluated for superfi cial lymph node size and checked for routine hematology (complete blood count) and serum chemistry (liver profi les; alanine aminotransferase and alkaline phosphatase levels, and kidney functions; blood urea nitrogen and creatinine levels) after each rescue phase. If dogs showed serious clinical signs, such as anorexia, vomiting, diarrhea or fever, and abnormal blood results, such as leukopenia, anemia, renal azotemia or increased serum levels of hepatic enzymes, then administration of the anti-neoplastic drug was stopped and supportive treatment was applied. The progression-free survival (PFS) was recorded from each dog during the rescue phase.
RNA isolation and cDNA synthesis
Total RNA was extracted from the WBC pellet using a Nucleospin RNA kit (MachereyNagel, Düren, Germany) according to the manufacturer's instructions. Contaminating genomic DNA in the RNA samples was removed by treatment with RQ1 RNase-Free DNase (Promega Corp., Madison, WI) at room temperature for 15 min to minimize the effect of pseudogenes. The RNA concentration was measured by a NanoDrop Lite spectrophotometer (Thermo Fisher Scientifi c, Waltham, MA) before converting to cDNA. Thereafter, cDNA was synthesized by Omniscript Reverse Transcription (Qiagen, Hilden, Germany) using 50 ng of total RNA in a fi nal volume 20 μl. All reactions were performed as recommended by the manufacturer's instructions. Samples were stored at -20 ºC until used.
Primer design and testing
The TATA box binding protein (TBP), beta actin (ACTB) and ribosomal protein S26 (RP S26) were chosen for normalization of the canine WBC pellet sample using the primer sequences (Table 2) as previously described [7, 20, 21] . To determine the best stability of these reference genes in the WBC pellets and individual variation in calibration samples, seven serial two-fold dilutions of the WBC pellet from each of three healthy dogs were performed. The evaluation of the candidate reference gene expression was calculated using fi ve algorithms; the comparative delta Ct method [22] , the geNorm [23] , Normfi nder [24] , BestKeeper [25] and RefFinder [26] . Canine ABCB1, ABCG2, Bax and Bcl2 primers (Table 2 ) were selected as previously described [5, 7, 21] . Conventional PCR was performed to confi rm the PCR conditions for amplifi cation effi ciency and specifi city, and subsequently used GoTaq Green Master Mix (Promega Corp.) with 0.4 μM of each primer and 2 μl of cDNA in a fi nal reaction volume of 25 μl. The PCR thermal cycling was performed as 39 cycles of 95 ºC for 30 s, 50-60 ºC as a gradient for 1 min and 72 ºC for 1.3 min using a C-Master Pro thermal cycler (Dynamica Scientifi c Ltd., Newport Pagnell, United Kingdom). Afterwards the PCR products were separated by 2% (w/v) agarose gel electrophoresis, imaged by UV transillumination in the presence of a distinct band and the product bands were cut out and purifi ed by Nucleospin extract II kit (Macherey-Nagel). The products were then sent for commercial DNA sequencing to the SolGent analysis service (SolGent Co. Ltd., Daejeon, Korea). The PCR amplifi cation was performed in a Rotor-Gene Q (Qiagen) with a thermal profi le of 95 ºC for 3 min followed by 40 cycles at 95 ºC for 3 s and 60 ºC for 30 s. The optimal temperature was determined by conventional PCR with temperature gradient from 50-60 ºC. The reaction was continued by a melting curve analysis, increasing the temperature stepwise each 5 s by 1 ºC, over the range of 65-95 ºC. A no template control and a positive control with known Cq value were included in each analysis to the assay specifi city and Cq variation. Analysis of the qRT-PCR results was then performed using the Rotor-Gene Q Series software (Qiagen), where the ΔΔCq method was used to determine the fold differences in concentration between the target gene of interest and the normalization gene.
Two-fold serial dilutions of the calibrator sample were performed in triplicate for each cDNA dilution (six dilutions range from 2 -1 to 2 -6 ng). The slope of the log-linear portion of the calibration curve was used to calculate the PCR amplifi cation effi ciency.
Data analysis
The signifi cance of variation in the transcript levels in canine lymphomas and relapsed/ refractory lymphomas, substage, histopathological grade and immunophenotype were analyzed by the Mann-Whitney U test. The infl uence of the clinical stage upon gene expressions levels was evaluated using the Kruskal-Wallis test. Wilcoxon-signed rank test was used to analyze the difference in gene expressions levels between pre-and post-rescue treatment dogs. The PFS was calculated from the initial rescue treatment until progressive disease or death from the treatment. The median PFS was noted and compared between low and high MRP transcript levels and the Bcl2/Bax ratio group, clinical stage, substage, histological grade and immunophenotype by KaplanMeier analysis with a log rank test. Alive dogs were censored when this study was analyzed. Statistics was performed using the SPSS statistics version 22 software (IBM Corporation, Armonk, NY), accepting signifi cance at a p value of ≤ 0.05.
RESULTS
Clinical data
The signalments of 14 dogs were summarized in Table 3 . They comprised six female (42.9%) and eight male (57.1%) dogs with a median of 7.5 years (range from 4-12 years). With respect to the lymphoma stage, nine (64.3%) were substage a (patients with no clinical signs) and fi ve (35.7%) were substage b (patients with clinical signs), while fi ve of each (35.7%) were stage III and stage IV, and four (28.6%) were stage V. For the phenotype, 10 (71.4%) were B-cell lymphomas and four (28.6%) were T-cell lymphomas. The overall response rate of the rescue protocol was 50%, where fi ve (35.7%) dogs had a complete remission, two of each (14.3%) had a partial response and stable disease, and the other fi ve (35.7%) dogs had a progressive disease and died after the initial treatment.
Amplifi cation effi ciency and specifi city of qRT-PCR
For PCR specifi city, the three internal reference genes and four genes of interest showed a single band of an appropriate size following agarose gel electrophoresis. The DNA sequences obtained from the PCR products were identical to the deposited gene sequences from the GenBank database (data not shown), while all the qRT-PCR reactions revealed a single melt peak in their respective melting curve analysis. For the PCR reaction effi ciency, all the primer pairs gave 90%-110% amplifi cation effi ciency, determined from the standard curve analysis of the two-fold serial dilutions. The three reference genes (TBP, ACTB and RP S26) could be amplifi ed from the WBC samples obtained from the fi ve healthy dogs of different ages, breeds, sex and body weight. However, after analyzing the data with the fi ve algorithms, TBP was found to be the most stable gene from the delta Ct, normFinder and geNorm (equal to RP S26) methods (data not shown), and therefore it was selected as the internal reference gene in this study. The subsequent expression of the mRNA levels of the fi ve genes (TBP, ABCB1, ABCG3, Bcl2 and Bax) was detected in all 21 samples with the highest mean Ct being 35.26 for ABCB1 transcript expression.
Relative expression levels of MRP (ABCB1 and ABCG2) genes in relapsed/refractory lymphomas, immunophenotyping and prognosis
The transcript levels of ABCB1 and ABCG2 were compared between lymphomas prior to the treatment and relapsed/refractory lymphomas. The median relative transcript levels of ABCB1 and ABCG2 in lymphomas prior to treatment were 1.62-and 1.95-fold lower, respectively, than the relapsed/refractory lymphomas ( Figure  1A ), although this was only signifi cantly different for ABCG2 (p = 0.01) and not for ABCB1 (p = 0.56).
Before rescue initiation, the T-cell lymphomas had 2.65-and 2.4-fold numerically higher ABCB1 and ABCG2 median relative transcript levels, respectively, than B-cell lymphomas, however; these were not signifi cant (p = 0.24 and 0.14, respectively, Figure 1C ). After the rescue treatment, relapsed/refractory lymphomas had median relative transcript levels of ABCB11.57-fold lower than in the pre-treatment (p = 0.4).
In addition, the ABCG2 transcript levels were decreased 1.85-fold after the rescue protocol (p = 0.87, Figure 2 ).
The transcripts levels of MRP (ABCB1 and ABCG2) in the pre-treatment lymphomas were numerically, but not signifi cantly, correlated with the PFS. The relapsed/refractory lymphomas with a low median transcript level of ABCB1 had a median PFS of 102 days compared to the high levels group with a median PFS of 79 days (p = 0.79), while the median PFS of the low ABCG2 transcript level group was 79 days compared to 25 days for the high expression group (p = 0.76).
Relative expression levels of Bax and Bcl2 and the Bcl2/Bax transcript ratio in relapsed/refractory lymphomas, immunophenotyping, and prognosis
Canine lymphomas had 1.74-fold higher median Bax transcript levels (p = 0.5), a 1.04-fold lower median Bcl2 expression (p = 0.75), and a 1.56-fold lower Bcl2/Bax ratio (p = 0.62) than relapsed/refractory canine lymphomas with no statistically signifi cant difference ( Figure 1B) .
When compared between B-and T-cell lymphoma, relapsing/refractory B-cell lymphomas had 1.23-fold lower median Bax transcript levels (p= 0.95) and 1.2-fold higher median Bcl2 transcript levels (p = 0.3) than T-cell lymphomas ( Figure 1D ). After the rescue treatment, relapsed/refractory lymphomas had 1.1-fold higher median relative transcript levels of Bax than in the pre-treatment (p = 0.4). Bcl2 transcript levels had 1.4-fold lower than in pre-treatment (p= 0.61). Thus, relapsed/refractory lymphomas had a 1.02-fold lower Bcl2/Bax ratio than in the pre-treatment (p= 0.74, Figure 2 ).
Overall the Bax and Bcl2 transcript levels and the Bcl2/Bax transcript ratio were not signifi cantly associated with the clinical outcome. The median PFS of the high Bcl2/ Bax ratio group was 102 days, whereas the low Bcl2/Bax ratio group had a lower median PFS of 79 days (p = 0.58) (Figure 3 ). Regarding to the two rescue treatment groups, there were no differences in transcript levels of all genes and PFS between groups (data not shown).
DISCUSSION
The overall response rate for this rescue treatment with toceranib phosphate was 50% and patients had an overall median PFS of 79 days. Many rescue drugs have been developed for the treatment of relapsed/refractory multicentric lymphomas. However, because of drug resistant overexpression induced by previous COP-or CHOP-based protocols, the DNA alkylating agent CCNU and L-asparaginase (a hydrolytic enzyme from bacteria) are commonly used to treat dogs with relapsed/refractory lymphomas [27] . Toceranib phosphate, a receptor TKI, is known to retard tumor growth and angiogenesis via inhibition of the vascular endothelial growth factor receptor, plateletderived growth factor receptor, Kit and Flt-3 [28] . It has been used to treat many tumors in dogs, including mast cell tumors, solid tumors, and lymphomas [9] [10] [11] . In human studies, TKIs inhibit the ATP binding site of receptor tyrosine kinases and prevent phosphorylation leading to cell death. They can block ABC drug transporter and possibly treat relapsed/resistant disease [29] . For example, Nilotinib has an inhibitory effect of the ABCB1 and ABCG2 function in chronic myeloid leukemia or Ponatinib shows the increased uptake of substrates of ABCB1 and ABCG2 [30, 31] . Zandvliet et al. (2013) reported that masitinib inhibited Pgp activity and reverted doxorubicin resistance in vitro. From our study, dogs that were resistant to the COP and CHOP protocols tended to have a lower transcript level of the drug resistance proteins, Pgp and BCRP (ABCB1 and ABCG2), after treatment with toceranib phosphate. However, further investigation with an increased number of cases is required.
Transcripts of ABCB1 and ABCG2 were detected in all WBC samples by qRT-PCR. From the three evaluated reference genes, TBP was found to be the most stable, followed by RP S26 and ACTB, as analyzed by RefFinder, and so TBP was chosen for normalization in this study, which is similar to previous studies [6, 7, 32] . When comparing the transcript levels of the two drug resistance proteins (ABCB1 and ABCG2) between canine multicentric lymphomas at the time of their diagnosis and at the fi rst time of relapse or becoming refractory to the current treatment, the ABCB1 and ABCG2 transcript levels were increased, consistent with that previously reported [6, 7] . T-cell lymphomas were found to have higher transcript levels of both ABCB1 and ABCG2 than B-cell lymphomas in this study. However, it has previously been reported that T-cell lymphomas show only an increased expression of ABCG2 [7] . In contrast, four out of ten dogs in the chemotherapy-resistant group increased expression of ABCB1 [6] . Nevertheless, the sample size of our study was small and we evaluated the transcript levels of MRPs in WBC samples, while they analyzed them from lymph node cytology samples. Moreover, the up-regulation of ABCB1 and ABCG2 transcript levels did not signifi cantly relate to a poor prognosis.
Inhibition of apoptosis is involved in tumor progression and leads to cytotoxic drug tolerance. In this study we detected changes in both Bax and Bcl2 mRNA transcript levels in relapsed and refractory canine lymphomas by qRT-PCR. Relapsed/ refractory lymphomas had overexpressed Bcl2 and downregulated Bax transcript levels compared to those lymphomas before the cytotoxic treatment. However, the Bcl2/Bax ratio was previously found to be a useful prognosis tool in both humans and dogs [17, 33] . Meichner et al. (2016) compared the ability to quantitatively detect the expressed protein and transcript levels of Bcl2 and Bax using Western blotting and fl ow cytometry for protein detection and qRT-PCR for transcript detection. The results were not different, and so transcript levels likely refl ected protein expression levels, but fl ow cytometry was superior due to its relative speed and coherent result. In this study we used qRT-PCR to detect transcript levels, but the results showed a high degree of variation. The trend of Bcl2/Bax transcript ratio was higher in B-cell than T-cell lymphomas. Dogs with a higher Bcl2/Bax transcript ratio than the median value tended to have shorter survival times, similar to a previous study [17] . The limitation of this study was the small sample size, which might be why it failed to predict the clinical outcome and prognosis.
High grade T-cell lymphomas have a poorer prognosis than high grade B-cell lymphoma due to shorter progression-free and survival times [34, 35] . The aggressive behavior of neoplastic T lymphocytes might be sensitive to overexpressed MRP and anti-apoptotic proteins. Programmed cell death occurs via intrinsic and extrinsic pathways. The extrinsic pathway is controlled by two phases which are death-stimuli dependent and degradation phases. After adaptor proteins are bound to the ligand of death receptors, the apoptotic signals are transduced and led to DNA fragmentation. The common cell death receptors are induced via Fas, Trail or TNF. Another apoptotic mechanism is intrinsic or mitochondrial pathway which is regulated by the Bcl2 protein family. When pro-apoptotic molecules, Bax and Bak, are activated, they trigger mitochondrial outer membrane permeabilization followed by release of cytochrome c and activation of caspases. The recent studies reported that Pgp could inhibit the activation of caspases in both T-lymphoblast cell lines and primary T-lymphocytes [36, 37] . In addition, T-leukemic cell lines were sensitive to Fas-mediated apoptosis by activation of caspase cascade opposite to B-cell lines that were resistant to Fas-and Trail-induced apoptosis [38] . Thus, ABCB1 expression might affect T-cell survival during the antineoplastic drug treatment. ABCG2 is commonly expressed in lymphoid malignancy. In humans, ABCG2 transcription levels were relevantly up-regulated after exposing with daunorubicin and mitroxantrone in T-cell acute lymphoblastic leukemia [39] . However, the study on the resistant mechanism induced by ABCG2 is limited in B-and T-cell lymphoma regardless to an effl ux transporter. The doxorubicin-based protocol is a treatment of choice in canine lymphomas; ABCG2 may play an important role in progressive diseases in dogs.
Many details are reported that Bcl2 family proteins are involved in the pathogenesis of both B-and T-cell lymphoma by escaping apoptosis due to Bcl2 overexpression and Bax/Bak downregulation. In a previous study, pro-apoptotic (Bax, Bak, Bid, and Bad) and anti-apoptotic (Bcl2 and Bcl-xl) clusters were investigated in human DLBCL. The pro-apoptotic profi les showed the higher expression in the germinal center B-cell lymphoma and could be used to identify subgroup of DLBCL [40] . The STATsignaling pathway regulates Bcl2 expression and cell survival in PTCL. Thus, specifi c target therapy with Bcl2 inhibitors is developed as a single or combination treatment to overcome the resistant disease in human lymphoid malignancies [41] .
In summary, the TKI toceranib phosphate concurrent with a rescue drug is likely to decrease the Pgp and BCRP (ABCB1 and ABCG2) expression levels in canine relapsed/ refractory lymphomas as well as anti-apoptosis molecules. However, increased amount of sample size is required to confi rm its potentiality to treat relapsed/refractory Band T-cell lymphomas.
ANALIZA TRANSKRIPTOMA ABCB1, ABCG2 I BCL2/BAX KOD LIMFMA PASA REFRAKTARNIH NA TERAPIJU I PASA U RELAPSU TOKOM TERAPIJE SIRINTRA Sirivisoot, PATHARAKRIT Teewasutrakul, ANUDEP Rungsipipat, SIRIKACHORN Tangkawattana, SOMPORN Techangamsuwan
Osnovni problemi vezani za nepostojanje odgorova na antitumorske lekova je rezistencija i povećana ekspresija antiapoptoičnih proteina u ćelijama tumora. U okviru protokola lečenja obavljena je evaluacije sposobnosti toceranib-fosfata konkurentnog sa lomustinom (CCNU) ili L-asparaginazom i vinkristinom, a u cilju smanjivanja rezistencije na lekove i apoptoične proteine kod limfoma pasa koji su bili ili u relapsu ili su bili potpuno refraktarni na tretman. Uzorci periferne krvi su uzimani pre i posle terapije od 14 pasa koji su bili refraktarni na tretman sa ciklofosfamid-vinkristin-prednisolonom (COP) ili COP-doksorubicinom (CHOP) i kod kojih su bili prisutni rekurentni multicentrični limfomi. Nivo ekspresije ABCB1, ABCG2, Bcl2 i Bax bio je određivan kvantitativnom real time -PCR metodom. Stepen promena nivoa ABCB1, ABCG2, Bcl2 i Bax analiziran je u korelaciji sa preživljavanjem bez progresije simptoma (PRS). U poređenju sa polaznim vrednostima, a posle tretmana, nivo ekspresije ABCB1 i ABCG2 informacone RNK bio je za 1,57 odnosno1,85 puta niži (p=0,4 i p=0,87). Odnos Bcl2/Bax je bio snižen ali ne značajno smanjen, 1.02 puta (p=0,74). Celokupan odgovor na ovaj protokol bio je 50% sa srednjom vrednošću PFS od 79 dana (u rasponu od 14 do 207 dana). Niske srednje vrednosti nivoa relativne ekspresije ABCB1, ABCG2 kao i proporcija Bcl/Bax grupe nije bio u korelaciji sa kliničkim ishodom u poređenju sa visokim srednjim vrednostima nivoa relativne ekspresije, a samim tim i sa kliničkim stanjem pacijenata, imunofenotipom, histološkim promenama i stadijumom bolesti. Otuda, primena lekova za tretman zajedno sa toceranib-fosfatom može da dâ pozitivne efekte u slučaju tretmana kod refraktarnih i pasa i pasa u relapsu.
